lyrica 150 mg/1 kapsula kapsula, tvrda
viatris bh d.o.o. - pregabalin - kapsula, tvrda - 150 mg/1 kapsula - 1 kapsula, tvrda sadrži: 150 mg pregabalina
lyrica 75 mg/1 kapsula kapsula, tvrda
viatris bh d.o.o. - pregabalin - kapsula, tvrda - 75 mg/1 kapsula - 1 kapsula, tvrda sadrži: 75 mg pregabalina
campto 20 mg/ml koncentrat za otopinu za infuziju
pfizer croatia d.o.o., slavonska avenija 6, zagreb - irinotekanklorid trihidrat - koncentrat za otopinu za infuziju - 20 mg/ml - urbroj: 1 ml koncentrata za otopinu za infuziju sadrži 20 mg irinotekanklorid trihidrata (što odgovara 17,33 mg irinotekana)
carboplatin pfizer 150 mg/15 ml koncentrat za otopinu za infuziju
pfizer croatia d.o.o., slavonska avenija 6, zagreb, hrvatska - karboplatin - koncentrat za otopinu za infuziju - 10 mg/ml - urbroj: jedna bočica sa 15 ml koncentrata sadrži 150 mg karboplatina (10 mg/ml)
lyrica 25 mg/1 kapsula kapsula, tvrda
viatris bh d.o.o. - pregabalin - kapsula, tvrda - 25 mg/1 kapsula - 1 kapsula, tvrda sadrži: 25 mg pregabalina
verzenios
eli lilly nederland b.v. - abemaciclib - neoplazme dojki - antineoplastična sredstva - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.
kisqali
novartis europharm limited - ribociklib sukcinata - neoplazme dojki - antineoplastična sredstva - kisqali je indiciran za liječenje žena s hormon receptor (h)‑pozitivan, людское эпидермическое ako uređaj primatelja 2 faktor rasta (her2)‑negativan lokalno-uobičajena ili metastatskih tumora dojke u kombinaciji s inhibitor aromataze, ili fulvestrant kao izvor endokrine terapije na temelju ili u žene koje su primili do hormonske terapije. u pre‑ ili perimenopauzi, endokrini terapija mora biti u kombinaciji s luteinizirajućeg hormona releasing hormon (lhrh) agonist.
emdofluxin, 50 mg/ml
emdoka, john lijsenstraat 16, b-2321 hoogstraten, belgija - fluniksin (u obliku fluniksinmeglumina) - otopina za injekciju - goveda, svinja i konja
trovex 1 mg/ml
emdoka bv, john lijsenstraat 16, 2321 hoogstraten, belgija - deksametazonizonikotinat - suspenzija za injekciju, za goveda, konje, svinje, mačke i pse - goveda, konja, svinja, mačaka i pasa
adempas
bayer ag - riociguat - hipertenzija, plućna - antihipertenzivi za plućnu arterijsku hipertenziju - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. učinkovitost je dokazana u populaciji uh uključujući etiologija idiopatskom ili nasljedne ili uh uh, povezane s bolestima vezivnog tkiva . paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.